

Hamlet Biopharma



This is Hamlet Biopharma

Innovative pharmaceutical company listed on Spotlight Stock Market



Ground breaking discoveries

Cancer and Infections



Strong drug development platform

Broad competence



Clinical validations

in both therapeutic areas



Rich pipeline

Broad project portfolio &
lower risk



Patents

15 patent families
About 100 individual patents



Publications


Ranked in the top 1 % world-wide
(Stanford ranking)

SIGNIFICANT PROGRESS


- **Successful development of the clinical programs**
- **Three Phase II trials with positive data**
 - Alpha1H treatment of bladder cancer*
 - Immunotherapy against infections*
 - Immunotherapy against pain*
- **Productive collaborations for commercialization**
- **International media coverage**
- **Media and communication/investor relations program**
- **Significant progress of our pipeline-strong new drug candidates**

Alpha1H: Bladder cancer therapy

A groundbreaking anti-cancer technology based on the synthetic Alpha1H peptide-oleate complex



Alpha1H – a synthetic peptide-based investigational new drug



The N-terminal domain of alpha-lactalbumin, which forms Alpha1H with oleic acid


Alpha1H reproduces the effects of HAMLET

Synthetic, GMP manufacturing, large quantities

International patents valid >2038

Therapeutic effects in animal models of cancer


Therapeutic effects in clinical trials of bladder cancer




Mechanism(s) of action – Alpha1H

- 1. Apoptosis-like death in tumor cells** (> 40 different cell types, cancer models and clinical studies).
- 2. Inhibition of cancer gene expression**
- 3. Activation of a broad, protective immune response**
similar to BCG therapy – the established bladder cancer treatment
- 4. Potent effects on metabolism**
 - Lipid and glucose metabolism
 - Reduced weight gain and blood glucose levels


Attacks tumor tissue
Triggers a therapeutic immune response
Affects metabolism
without damaging healthy tissues



Early bladder Cancer (NIMBC) is treated by TURB followed by repeated intravesical instillations of suitable therapies



- Intravesical Alpha1H as neoadjuvant
- Adjuvant
- Combination therapy



Successful development of Alpha1H for bladder cancer

On September 11, 2024, Hamlet BioPharma announced the publication of the full analysis of these Phase II clinical results in Cancer Medicine <https://doi.org/10.1002/cam4.70149>.


Treatment resulted in a significant reduction in tumor size in 88% of tumors treated with the higher dose and 47% of tumors treated with the lower dose of Alpha1H.

No significant drug-related adverse events were detected.



Fast Track status for Alpha1H from the FDA.

Hamlet BioPharma is now proceeding to optimize the design of Phase III clinical trials in dialogue with the FDA.













Alpha1H – tumor response, dose-escalation study



Alpha1H– tumor response, dose-escalation study, Part II





Positive data in three Phase II trials

Product candidate	Indication	Discovery	Preclinical	Clinical	Phase II	Phase III
Alpha1H	Bladder cancer					
IL-1 receptor antagonist (anakinra)	Bladder pain syndrome					
IL-1 receptor antagonist (anakinra)	Recurrent acute cystitis					

We show that immunotherapy is an alternative to antibiotics

Infections cause disease and mortality, world-wide



<http://phenomena.nationalgeographic.com/2016/06/23/colistin-resistance-the-pig-is-out-of-the-barn/>

Groundbreaking results in Phase II trial of recurrent cystitis- similar effects of immunomodulation and antibiotics

On September 26, 2024, Hamlet BioPharma announced new positive results from the Phase II clinical trial conducted in patients with recurrent bacterial urinary tract infections.

The study compared immunomodulation therapy with anakinra (IL-1RA) to antibiotic treatment. There was no difference in efficacy between the two treatments.

Both treatments effectively reduced the symptoms and recurrence rates and improved the quality of life in treated patients.

Immunotherapy may therefore represent an alternative to antibiotics

- reducing the need for antibiotic treatment in this patient group.
- reducing the selective pressure on antibiotic resistant bacteria
- reducing the side effects on the normal flora in individual patients and in the population

Strong protective effects against antibiotic resistant bacteria

IL1-RA treatment of antibiotic-resistant bacteria in an animal model

Hamlet BioPharma has previously published a study showing that treatment with the drug anakinra (IL-1RA) prevents severe infections of the urinary tract in a murine model relevant to human disease including kidney infections that may cause sepsis.

The treatment was efficient also against infections caused by ***antibiotic resistant bacteria***, defining this therapy as an alternative or complement to antibiotics.

Successful development of the clinical program

Phase II trial of immunomodulation in bladder pain syndrome

IL1-RA treatment of bladder pain syndrome

On May 6, 2024, Hamlet BioPharma published clinical data from patients with bladder pain syndrome supporting anakinra (IL1-RA) as a new, successful treatment option.

The company announced that a significant proportion of the patients with bladder pain syndrome (severe pain in the urinary bladder), treated with anakinra in a placebo-controlled study, have responded positively to the treatment.

Productive collaborations for commercialization

Partnerships and commercial opportunities

- Hamlet BioPharma continues to drive the clinical programs forward with the goal of bringing these innovative therapies to market.
- Strategic alliances and commercial collaborations for our core assets in cancer and infections continue to be a key focus area for the company.
- The recent positive Phase II data puts renewed emphasis on the cancer and immunotherapy projects as well as the portfolio of preclinical projects.

International media /communications

On September 12, 2024, The Economist, a leading international journal, published an article on breast milk, mentioning and describing HAMLET and progress and the clinical results.

On November 4, 2024, Hamlet BioPharma was featured in **CEO World Magazine** and **Pulse 2**, renowned for their focus on high-level executives and influential business leaders.

They highlighted Hamlet's recent clinical trials and innovative approach merging groundbreaking research with a strong business vision.

Pipeline – 15 projects, all with proven therapeutic efficacy in animal models


Cutting- edge drug development pipeline: targeting cancer, infections and inflammation

Clinical		
Alpha1H	Bladder cancer	Phase II: Non-muscle Invasive Bladder Cancer
IL-1 receptor antagonist	Inflammation and pain	Phase II: Bladder Pain Syndrome
IL-1 receptor antagonist	Infection	Phase II: Recurrent Acute Cystitis
Pre-clinical		
Alpha1H	Brain tumor	Positive data in animal model, development of technology
Hamlet	Colon and rectal cancer	Positive data in animal model
Hamlet	Oral cancer	Preclinical evaluation
NK1R-receptor antagonist	Pain and nerve activation inhibitors	Positive data in animal model, development of technology. Preparation of substance for clinical studies
RNA Pol II inhibitor - protein	Preventive anti-inflammatory and antibacterial effects	Positive data in animal model, development of technology. Preparation of substance for clinical studies
RNA Pol II inhibitor - bacteria	Prevention of inflammation and treatment of infection	Positive data in animal model, development of technology
IRF7 inhibitor, siRNA	Inhibits severe bacterial infections	Positive data in animal model, technology development. Data to support the development of drugs for clinical trials
Anti-TBC peptide	Pulmonary tuberculosis	Positive data in animal model, development of technology for drug production

SUMMARY – Our Cancer & Infectious Disease treatments

- Hamlet BioPharma is a **leading new pharmaceutical company** with a **robust pipeline of drug candidates and patents** poised to advance **the treatment of cancer and infectious diseases**.
- Our commitment **to innovation and cutting-edge research** uniquely positions us to develop **breakthrough therapies** that are **both highly effective and safer for the patients**.
- We have **15 drug candidates** in our pipeline, including **three with successful Phase II clinical data**. Our successful Phase II trials demonstrate our **ability to translate scientific discoveries into tangible clinical results**.
- We **collaborate with leading international firms to accelerate the commercialization** of our assets and bring our therapies to patients worldwide. **The activity level is high**.

THE TEAM





**Thank you
for your
attention**

Hamlet Pharma's investor relations

Quarterly report press briefings

Hamlet BioPharma invites to a digital press briefings after the publication of the each quarterly report. The video presentation is available at the company's website:

<https://hamletbiopharma.com/news/media-archive/>

Monthly investor meetings with the company

Hamlet BioPharma invites to monthly investor meetings where the experts responsible for the different technologies and projects present their work.

The video presentation is available at the company website:

<https://hamletbiopharma.com/news/media-archive/>